AndreaBozzo/ceres-open-data-index huggingface dataset:
Compound 530214: N-Acetylhistamine, TMS

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 2-acetamido-3-(1-trimethylsilylimidazol-4-yl)propanoate. Molecular Formula: C14H27N3O3Si2. Molecular Weight: 341.55. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Baltimore-Towson, MD

This report presents combined 2005 to 2010 National Survey on Drug Use and Health (NSDUH) results for those aged 12 or older in the Baltimore-Towson, Maryland metro area. The report includes estimates of substance use disorder, major depressive episode, illicit drug use, marijuana use, cigarette use, binge alcohol use, and the nonmedical use of prescription-type pain relievers. Results are provided for Baltimore-Towson, Maryland, and the U.S. overall.
NNDSS - TABLE 1DD. Rubella to Rubella, congenital syndrome

NNDSS - TABLE 1DD. Rubella to Rubella, congenital syndrome - 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

•	These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
• Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html.
•	The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
Characterization of alternatively spliced products and tissue-specific isoforms of USP28 and USP25

Background
          The ubiquitin-dependent protein degradation pathway is essential for the proteolysis of intracellular proteins and peptides. Deubiquitinating enzymes constitute a complex protein family involved in a multitude of cellular processes. The ubiquitin-specific proteases (UBP) are a group of enzymes whose predicted function is to reverse the ubiquitinating reaction by removing ubiquitin from a large variety of substrates. We have lately reported the characterization of human USP25, a specific-ubiquitin protease gene at 21q11.2, with a specific pattern of expression in murine fetal brains and adult testis.
        
        
          Results
          Database homology searches at the DNA and protein levels and cDNA library screenings led to the identification of a new UBP member in the human genome, named USP28, at 11q23. This novel gene showed preferential expression in heart and muscle. Moreover, cDNA, expressed sequence tag and RT-PCR analyses provided evidence for alternatively spliced products and tissue-specific isoforms. Concerning function, USP25 overexpression in Down syndrome fetal brains was shown by real-time PCR.
        
        
          Conclusions
          On the basis of the genomic and protein sequence as well as the functional data, USP28 and USP25 establish a new subfamily of deubiquitinating enzymes. Both genes have alternatively spliced exons that could generate protein isoforms with distinct tissue-specific activity. The overexpression of USP25 in Down syndrome fetal brains supports the gene-dosage effects suggested for other UBP members related to aneuploidy syndromes.
Hospital Cost Report Audited Data: 2010

This version of the Institutional Cost Report (ICR) has been audited by a Certified Public Accounting Firm.  The ICR is a uniform report completed by New York State hospitals to report income, expenses, assets, liabilities, and statistics to the  the Department of Health (DOH).  Under DOH regulations, (Part 86-1.2), Article 28 hospitals are required to file financial and statistical data with DOH annually.  The data filed is part of the ICR and is received electronically through a secured network.  This data is used to develop Medicaid rates, assist in the formulation of reimbursement methodologies, and analyze trends. For more information, check out:  http://www.health.ny.gov/facilities/hospital/index.htm.
Compound 530371: 1,2-Propanediol, 3-(4-hydroxyphenyl), tris-TMS

Chemical compound data from PubChem database. IUPAC Name: trimethyl-[1-trimethylsilyloxy-3-(4-trimethylsilyloxyphenyl)propan-2-yl]oxysilane. Molecular Formula: C18H36O3Si3. Molecular Weight: 384.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529374: Trp isoBOC TBDMS

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 3-(1H-indol-3-yl)-2-(2-methylpropoxycarbonylamino)propanoate. Molecular Formula: C22H34N2O4Si. Molecular Weight: 418.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Managed Care Institutional Provider Network Data: December 31, 2017

The primary purpose for the Provider Network Data System is to collect data needed to evaluate the provider networks including physicians, hospitals, labs, home health agencies, durable medical equipment providers, etc., for all types of health plans in New York State. Beginning in 2017, the PNDS includes Medicaid Managed Care (MMC), HIV Special Need Plans (SNP), Health and Recovery Plans (HARP), Child Health Plus (CHP), Programs of All-Inclusive Care for the Elderly (PACE), Non-PACE Managed Long-Term Care (MLTC) plans, Qualified Health Plans (QHP), Essential Plans (EP), and commercial plans. This dataset reflects institutional provider data. Provider Network Data System information is self-reported by health plans. The PNDS data dictionary can be found at http://www.health.ny.gov/health_care/managed_care/docs/dictionary.pdf . To use the NYS Provider & Health Plan Look-Up Tool, click on the following link: https://pndslookup.health.ny.gov/ .
Evidence for large domains of similarly expressed genes in the

Background
          Transcriptional regulation in eukaryotes generally operates at the level of individual genes. Regulation of sets of adjacent genes by mechanisms operating at the level of chromosomal domains has been demonstrated in a number of cases, but the fraction of genes in the genome subject to regulation at this level is unknown.
        
        
          Results
          Drosophila gene-expression profiles that were determined from over 80 experimental conditions using high-density oligonucleotide microarrays were searched for groups of adjacent genes that show similar expression profiles. We found about 200 groups of adjacent and similarly expressed genes, each having between 10 and 30 members; together these groups account for over 20% of assayed genes. Each group covers between 20 and 200 kilobase pairs of genomic sequence, with a mean group size of about 100 kilobase pairs. Groups do not appear to show any correlation with polytene banding patterns or other known chromosomal structures, nor were genes within groups functionally related to one another.
        
        
          Conclusions
          Groups of adjacent and co-regulated genes that are not otherwise functionally related in any obvious way can be identified by expression profiling in Drosophila. The mechanism underlying this phenomenon is not yet known.
Malarone treatment failure and

We report the first in vitro and genetic confirmation of Malarone® (GlaxoSmithKline; atovaquone and proguanil hydrochloride) resistance in Plasmodium falciparum acquired in Africa. On presenting with malaria two weeks after returning from a 4-week visit to Lagos, Nigeria without prophylaxis, a male patient was given a standard 3-day treatment course of Malarone®. Twenty-eight days later the parasitaemia recrudesced. Parasites were cultured from the blood and the isolate (NGATV01) was shown to be resistant to atovaquone and the antifolate pyrimethamine. The cytochrome b gene of isolate NGATV01 showed a single mutation, Tyr268Asn which has not been seen previously.
Patent AT-E39988-T1: [Translated] ROTARY SEAL WITH BALANCED SEALS.

A rotary joint for use with rotating heat exchanger drums particularly suitable for installations utilizing higher fluid pressures, temperatures and rotative speeds. The joint (12) includes a nipple (10) mounted upon the drum shaft (32) having an enlarged diameter portion within a body chamber (42) upon which a pair of seals (74, 76) are mounted having differential pressure faces to balance fluid medium pressures imposed upon the seals (74, 76), seal wear does not produce relative axial displacement between the nipple (10) and body (12), and concentric alignment between the nipple (10) and body (12) is maintained by axially spaced alignment bushings (58, 68) interposed therebetween.
Compound 527541: 2,5-Dimethyl-1-pentan-3-ylpyrrole

Chemical compound data from PubChem database. IUPAC Name: 2,5-dimethyl-1-pentan-3-ylpyrrole. Molecular Formula: C11H19N. Molecular Weight: 165.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527378: 20,26-Dimethyl-nonacosyl cyanide

Chemical compound data from PubChem database. IUPAC Name: 21,27-dimethyltriacontanenitrile. Molecular Formula: C32H63N. Molecular Weight: 461.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Activation of the peroxisome proliferator-activated receptor α protects against myocardial ischaemic injury and improves endothelial vasodilatation

Background
          The peroxisome proliferator-activated receptor α (PPARα) plays an important role in the metabolism of lipoproteins and fatty acids, and seems to protect against the development of atherosclerosis. To evaluate the possible protective role of PPARα on cardiovascular function, the effect of the PPARα agonist, fenofibrate was assessed with respect to ischaemia/reperfusion injury and endothelial function in mice.
        
        
          Results
          Fenofibrate treatment reduces myocardial infarction size and improves post-ischaemic contractile dysfunction. Hearts from PPARα null mice exhibit increased susceptibility to ischaemic damages and were refractory to protection by fenofibrate treatment suggesting that the beneficial effects of fenofibrate were mediated via PPARα. Furthermore, fenofibrate improves endothelium- and nitric oxide-mediated vasodilatation in aorta and mesenteric vascular bed. A decreased inhibitory effect of reactive oxygen species in the vessel wall accounts for enhanced endothelial vasodilatation. However, the latter cannot be explained by an increase in nitric oxide synthase expression nor by an increase sensitivity of the arteries to nitric oxide.
        
        
          Conclusions
          Altogether the present data suggest that fenofibrate exerts cardioprotective effect against ischaemia and improves nitric oxide-mediated response probably by enhancing antioxidant capacity of the vessel wall. These data underscore new therapeutic perspectives for PPARα agonists in ischaemic myocardial injury and in cardiovascular diseases associated with endothelial dysfunction.
Delay or nonreceipt of needed medical care, prescription drugs, or dental care during the past 12 months due to cost: United States

Data on delay or nonreceipt of needed medical care, nonreceipt of needed prescription drugs, or nonreceipt of needed dental care during the past 12 months due to cost by selected population characteristics. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time. 

SOURCE: NCHS, National Health Interview Survey, Family Core, Sample Child, and Sample Adult questionnaires. Data for level of difficulty are from the 2010 Quality of Life, 2011-2017 Functioning and Disability, and 2018 Sample Adult questionnaires. For more information on the National Health Interview Survey, see the corresponding Appendix entry at https://www.cdc.gov/nchs/data/hus/hus19-appendix-508.pdf.
Patent AT-E401060-T1: [Translated] QUICKLY DISSOLVING TABLET

The present invention relates to rapidly disintegrating tablets intended to be used as orodispersible tablets or dispersible tablets. They are ingested either by dispersing directly in the mouth or in water. The tablets include silicified microsrystalline cellulose. They are especially suitable for antibiotics. These tablets are also suitable for use in pediatric patients in the age above 3 years. For pediatric patients under 3 years the same tablets can be used as dispersible tablets. Rapidly disintegrating tablets which contain amoxicillin and clavulanic acid are also described.
Compound 525405: 2-Methyl-3,5-dithianonane

Chemical compound data from PubChem database. IUPAC Name: 1-(propan-2-ylsulfanylmethylsulfanyl)butane. Molecular Formula: C8H18S2. Molecular Weight: 178.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Release of annexin V-binding membrane microparticles from cultured human umbilical vein endothelial cells after treatment with camptothecin

Background
          Elevated plasma counts of endothelial microparticles (MP) have been demonstrated in various diseases with a vascular injury component. We used flow cytometry to study the MP-release from cultured human umbilical vein endothelial cells (HUVEC) stimulated by various agonists. MP-release by a topoisomerase I inhibitor camptothecin has been studied in detail.
        
        
          Results
          Overnight stimulation of HUVEC with either LPS or TNFα, or 30 min stimulation with thrombin, phorbol-myristate-acetate, tissue plasminogen activator, or angiotensin-II did not cause a significant release of annexin V-binding MP. In contrast, induction of apoptosis with 5 μM camptothecin, documented by 60–70% desquamation of HUVEC culture, annexin V-binding to the cells and DNA-fragmentation, led to a release of annexin V-binding microparticles (~80,000 MP/103 cells). This microparticle-release was prevented by Z-Val-Ala-Asp-fluoromethyl-ketone (ZVAD). Lower concentration of camptothecin (500 nM) induced comparable microparticle-release without loss of the culture confluence and without increase in annexin V-binding to the cells or DNA-fragmentation. Analyzed microparticles were free of nucleic acids and 95% of microparticles were 0.3–1 μm in size. Double-labeling flow cytometry assay showed that all annexin V-binding Microparticles expressed CD59 but only approximately 50% of these also expressed CD105.
        
        
          Conclusions
          Camptothecin treated HUVEC released different populations of annexin V-binding membrane microparticles at early stage after proapoptotic stimulation before detection of phosphatidylserine exposure on the cells or DNA fragmentation. The microparticle-release was ZVAD sensitive but was not enhanced at the executive phase of apoptosis. These observations offer a new insight into microparticle-release as a marker of endothelial stimulation and injury.
Patent AT-E401726-T1: [Translated] MULTI CARRIER SYSTEM WITH STORED APPLICATION PROFILES TO SUPPORT MULTIPLE APPLICATIONS

A transceiver and method for communicating over a communications channel having a plurality of subchannels are described. In particular, the transceiver is capable of dynamically switching between communicating data for a first active application set and communicating data for a second different active application set. As part of communicating data for the first active application set, the transceiver allocates the subchannels to the one or more applications in the first application set. When the transceiver dynamically transitions to communicating data for the second different application set, the transceiver reallocates the subchannels to the one or more applications in the second different application set. In one embodiment the transceiver modifies the data'rates of subchannels in the Bit Allocation Table according to the transmission requirements of the application whose data is being transmitted on the particular subchannel. In another embodiment, the transceiver is capable of dynamically switching from transmitting data for an Internet access application to transmitting data for a voice telephony application in addition to the Internet access application. In a further embodiment, the ABCD voice telephony signaling bits can be transmitted with either the data from the Internet access application or the data from the voice telephony application.
NSDUH 2017 Person-Level Sampling Weight Calibration Report

This report contains a brief review of the sampling weight calibration methodology used for the 2017 National Survey on Drug Use and Health (NSDUH). This report also lists detailed documentation on the implementation steps and evaluation results from the weight calibration application. The constrained exponential modeling (CEM) method used in the surveys before 1999 (referred to in this report as the generalized exponential model [GEM]) was modified to provide more flexibility in dealing internally with the extreme weights and for setting bounds directly on the weight adjustment factors so they can become suitable for nonresponse (nr) and poststratification (ps) adjustments.
Patent AT-E399666-T1: [Translated] METHOD FOR DETECTING AN OBJECT IN A DOOR OPENING OF A VEHICLE

The method involves triggering a vehicle reaction if a signal received in a sensor arrangement deviates from a desired value. An updated desired value is determined with the door closed after driving off. The vehicle reaction is only triggered in a period between closing the door and the end of a customer-specific selected period (3) starting with the next time the vehicle is driven off after closing the door.
Drug-Involved Mortality (DIM) data available through the Research Data Center (RDC)

The Drug-Involved Mortality (DIM) data are an enhancement to the National Vital Statistics System, Mortality data providing information on substances, as well as prescription (using generic names only – no trademarks) and illicit drugs mentioned on death certificates of residents of the United States and the District of Columbia. Data files were created by examining the literal text of three fields on the death certificate:  Part I-Cause of Death, Part II –Significant Conditions Contributing to Death and Box 43, a verbatim description of how the injury occurred. The DIM data system does not support individual examination of “literal text” and the actual variables showing free-form text are not included in these files.
Patent AT-E401743-T1: [Translated] METHOD FOR CODING MOVING IMAGES AND METHOD FOR DECODING MOVING IMAGES

A moving picture coding apparatus includes a motion estimation unit (101) for performing motion estimation by fixing the one of two reference pictures as a reference picture indicated by an inputted default reference picture number DefRefNo and a variable length coding unit (107) for performing variable length coding on coded residual data ERes, a prediction type PredType, a reference picture number RefNo2 and motion vectors MV1, MV2 on a block-by-block basis, and outputting them as coded moving picture data Str.
Hospital Inpatient Discharges (SPARCS De-Identified): Potentially Preventable Complication (PPC) Group Rates by Hospital: Beginning 2013

The dataset groups 66 individual Potentially Preventable Complication (PPC) measures into 8 different categories, providing observed and risk-adjusted rates for all payer discharges by hospital and statewide, beginning in 2013. 

Potentially Preventable Complications (PPC), obtained from software created by 3M Health Information Systems, are defined as harmful events or negative outcomes that develop or occur during hospitalization and may result from processes of care and treatment rather than from natural progression of the underlying illness. 

The PPCs were calculated using Statewide Planning and Research Cooperative System (SPARCS) inpatient data.
Compound 530007: Trimethyl-[(13-methyl-3-trimethylsilyloxy-1,2,3,4,5,6,7,8,9,10,11,12,14,15,16,17-hexadecahydrocyclopenta[a]phenanthren-17-yl)oxy]silane

Chemical compound data from PubChem database. IUPAC Name: trimethyl-[(13-methyl-3-trimethylsilyloxy-1,2,3,4,5,6,7,8,9,10,11,12,14,15,16,17-hexadecahydrocyclopenta[a]phenanthren-17-yl)oxy]silane. Molecular Formula: C24H46O2Si2. Molecular Weight: 422.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Publications Using SAMHSA Data2012 Uniform Reporting System (URS) Tables for Federated States of Micronesia

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2012. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.